Physician profile
Mark J Gabriel
NPI 1982642724
$2,910.31
in general payments reported to CMS, 2019-2025
22 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $70.78 · 2021: $31.00 · 2022: $171 · 2023: $511 · 2024: $353 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $590.86 | 2019-2025 | Xifaxan |
| Abbvie INC. | $526.74 | 2019-2025 | |
| Madrigal Pharmaceuticals | $229.64 | 2025 | Rezdiffra |
| Celgene Corporation | $193.77 | 2023 | Zeposia |
| Pfizer INC. | $192.63 | 2019-2024 | |
| Gilead Sciences, INC. | $137.94 | 2019-2025 | |
| Shionogi INC | $130.05 | 2019 | |
| Janssen Biotech, INC. | $124.05 | 2022-2025 | Tremfya, Simponi, Stelara |
| Ardelyx, INC. | $115.52 | 2024-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $107.87 | 2019-2025 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $88.13 | 2019-2025 | Entyvio |
| Braintree Laboratories, INC. | $86.18 | 2019-2025 | Suflave, Sutab |
| Genzyme Corporation | $71.15 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $60.55 | 2024-2025 | Voquezna |
| Phadia US INC. | $55.70 | 2024-2025 | Immunocap |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $51.73 | 2022-2025 | Dupixent |
| Allergan, INC. | $33.20 | 2019 | |
| Intercept Pharmaceuticals, INC. | $33.03 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $28.06 | 2022 | |
| Redhill Biopharma INC. | $19.50 | 2024 | Talicia |
| Shire North American Group INC | $18.53 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gabriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.